<DOC>
	<DOCNO>NCT02146261</DOCNO>
	<brief_summary>This study ( Protocol No . E6011-J081-002 ) single-center , randomize , double-blind , placebo-controlled , single ascend dose ( SAD ) study evaluate mainly safety tolerability single subcutaneous administration E6011 . A total 32 subject randomize four cohort ( 50 , 100 , 200 400 mg group ) . Of eight subject per cohort , six subject receive single subcutaneous E6011 administration two subject receive single subcutaneous placebo administration .</brief_summary>
	<brief_title>A Phase 1 Study Single-dose Subcutaneous E6011 Japanese Healthy Adult Male Subjects</brief_title>
	<detailed_description>This study consist Screening Period , Observation Period , In-patient Period , Follow-up Period . Screening assessment perform within 28 2 day start study treatment , Observation Period assessment perform day start study treatment confirm eligibility study subject . The eligible subject randomize either E6011 arm placebo arm use drug allocation list prepared random code statistician . Each subject dose interval least 30-minutes .</detailed_description>
	<criteria>Inclusion criterion 1 . Nonsmoking Japanese male subject age great equal 20 less 45 year 2 . BMI screen great equal 18.5 kg/m2 less 25.0 kg/m2 3 . Males successful vasectomy female partner must agree practice highly effective contraception throughout study period Exclusion criterion 1 . Has treat biologic product ( ) ( except immunoglobulin ) 2 . Has receive immunoglobulin blood preparation within 6 month study treatment 3 . Has receive inoculation within 4 week study treatment 4 . Has history autoimmune disease immunodeficiency 5 . Has history clinically significant angioedema , hematemesis , anal hemorrhage , hemoptysis 6 . Has history acute myocardial infarction , cerebral infarction , cerebral hemorrhage , arteriosclerosis obliterans 7 . With gross hematuria , occult bleed urine great equal 1+ urine protein great equal 1+ , either great equal 2+ find screen 8 . Has clinically significant vasculitis ( e.g. , mononeuritis multiplex ) 9 . Known positive human immunodeficiency virus antigen/antibody ( HIV antigen/antibody ) , hepatitis B virus surface antigen ( HBs antigen ) , hepatitis B virus surface antibody ( HBs antibody ) , hepatitis B core virus antibody ( HBc antibody ) , hepatitis B virus ( HBV ) DNA , hepatitis C virus antibody ( HCV antibody ) , human T cell lymphotropic virus type 1 antibody ( HTVL1 antibody ) , syphilis serology test positive screening . 10 . Known positive tuberculosis test ( Tspot.TB Test QuantiFERON TB Gold Test ) screening . 11 . Treated ethical drug ( except disinfectant , eye drop ) within 4 week study treatment . 12 . Treated nonprescription drug ( except disinfectant , eye drop ) within 2 week study treatment . 13 . Has participate another clinical trial receive investigational drug device within 16 week study treatment . 14 . Received blood transfusion within 1 year , 400 mL whole blood donation within 12 week , 200 mL whole blood donation within 4 week , blood constituent donation within 2 week study treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Volunteers</keyword>
	<keyword>Japanese</keyword>
	<keyword>Males</keyword>
</DOC>